Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,389.3
-63.7 (-2.60%)

 

  • STI Straits Times Index
    2,389.3
    -63.7 (-2.60%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,330.7
    -0.2 (-0.02%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,236.1
    -44.0 (-0.19%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,764.0
    -16.7 (-0.60%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    17,820.2
    1.5 (0.01%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,623.4
    91.7 (2.02%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,324.3M
  • Value: 1,512.2M
  • Rise: 65
  • Fall: 270
  • Unch: 476

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.095-0.001
ESR-REIT0.250-0.015
Genting Sing0.650-0.015
Mapletree Com Tr1.500-0.120
CapitaMall Trust1.520-0.100
Interra Resource^0.042+0.001
Singtel2.580-0.040
Medtecs Intl0.095+0.005
AusGroup^0.021-0.003
JCG Investment0.002-

World Indices

World Indices
Name Last Change
Nasdaq 7,373.1 -114.2
HSI 23,236.1 -44.0
HSCEI 9,491.1 -35.5
Jakarta 4,623.4 +91.7
Nikkei 225 17,820.2 +1.5
SSE Comp 2,764.0 -16.6
Shanghai A 2,896.6 -17.5
Shanghai B 216.0 -0.8
KOSPI 1,725.4 +0.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 03 Apr 2020 16:08
Last (SGD): 0.185 Change: -0.005 High: 0.195 Remarks: -
Change (%): -2.63 Low: 0.185
Open 0.195 Yesterday's Close 0.190
Buy Price 0.185 Sell Price 0.194
Buy Volume ('000) 0.5 Sell Volume ('000) 19.0
Cumulative Volume ('000) 5.0 Cumulative Value 960
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02174 Trailing EPS (SGD) e 0.02174 NAV (SGD) b 0.1467
PE a 8.510 Trailing PE f 8.511 Price / NAV b 1.2611
Dividend (SGD) d 0.010000 Cash In Hand (SGD) g 0.0871 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 5.405 Price / Cash In Hand g 2.124 Treasury Shares h -
Beta - 75 Daysi 0.312 R-Squared - 75 Days(%)i 3.61 Market Cap (M) 55.580
Beta - 500 Daysi 0.297 R-Squared - 500 Days (%)i 1.62 Enterprise Value (M) 32.914
Piotroski F Score 6 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 26.1473 6-Month VWAP 0.231 Free Float (%) 20.1
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 28 Feb 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 55.580 8.510 8.511 1.2611 5.405
Industry Medical & Biotechnology SGX 897.005 18.297 19.032 1.1811 2.269
Pharmaceuticals: Major SGX 51.615 1219.246 128.501 2.1751 1.940
Local Peer IX Biopharma SGX 94.090 - - 6.2232 -
Local Peer Pharmesis Intl SGX 5.175 - - 0.4314 -
Global Peer JOHNSON & JOHNSON NYSE 353,719.079 23.123 23.396 5.9478 2.664
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 211,390.063 16.724 17.990 3.8106 2.014
Global Peer MERCK & CO INC NYSE 193,390.587 31.092 19.648 7.4648 2.668
Global Peer PFIZER INC NYSE 186,622.610 16.734 11.469 2.9564 4.227
Global Peer ELI LILLY AND COMPANY NYSE 133,659.927 41.355 28.819 51.2721 1.779
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 125,634.404 25.535 36.532 2.4349 2.081
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 115,370.822 53.627 85.903 8.7888 3.009
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 112,419.743 22.063 35.868 1.6994 2.561
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 111,455.590 18.229 19.074 12.8829 1.900
Global Peer ABBVIE INC NYSE 108,343.278 19.152 13.821 -13.2578 5.392
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), SINOPHARM (HKEx), INNOVENT BIO-B (HKEx), REPLIGEN CORP (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), SH PHARMA (HKEx), FORTY SEVEN INC (NASDAQ), BAIYUNSHAN PH (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), CANSINOBIO-B (HKEx), CHINARES PHARMA (HKEx), JUNSHI BIO-B (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CMS (HKEx), HENLIUS-B (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SSY GROUP (HKEx), RA PHARMACEUTICALS INC (NASDAQ), ALLAKOS INC (NASDAQ), TRAD CHI MED (HKEx), INNOCARE-B (HKEx), CHINAGRANDPHARM (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), ZYMEWORKS INC (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), TONGRENTANGCM (HKEx), CKLIFE SCIENCES (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), CSTONE PHARMA-B (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), PETIQ INC (NASDAQ), ATHENEX INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), SHINEWAY PHARM (HKEx), QUANTERIX CORPORATION (NASDAQ), AC IMMUNE SA (NASDAQ), IGBB (Bursa), Kimia Farma Tbk. (IDX), RELMADA THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), PROVENTION BIO INC (NASDAQ), HUA MEDICINE-B (HKEx), G1 THERAPEUTICS IN (NASDAQ), FUSEN PHARM (HKEx), CRINETICS PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), 89BIO INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), LANNETT CO INC (NYSE), SATSUMA PHARMACEUTICALS INC (NASDAQ), IMARA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), DURECT CORP (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), DAWNRAYS PHARMA (HKEx), TOT BIOPHARM-B (HKEx), GRITSTONE ONCOLOGY INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), BSTEAD (Bursa), VERU INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), CH BIOTECH-20K (HKEx), OVID THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CH BIOTECH-5K (HKEx), BIOMX INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), ARTARA THERAPEUTICS INC (NASDAQ), EVOLUS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), ZHONGZHIPHARM (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PYC THERAPEUTICS LIMITED (ASX), TYME TECHNOLOGIES INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NC HEALTHCARE (HKEx), OBSEVA SA (NASDAQ), GAMIDA CELL LTD (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), PAK FAH YEOW (HKEx), CHARMACY PHAR (HKEx), HARROW HEALTH INC (NASDAQ), NEW RAY MEDIC (HKEx), MILLENDO THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), TFF PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMMUNIC INC (NASDAQ), GENPREX INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), AQUESTIVE THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), Merck Tbk. (IDX), Phapros Tbk. (IDX), EYENOVIA INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), NEP INTERLONG (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ONCTERNAL THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), PALLA PHARMA LTD (ASX), PURAPHARM (HKEx), MEDIWOUND LTD (NASDAQ), BAUDAX BIO INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), SANAI HEALTH GP (HKEx), CNS PHARMACEUTICALS INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), HOTH THERAPEUTICS INC (NASDAQ), NOVA (Bursa), MEDLAB CLINICAL LIMITED (ASX), ENTERA BIO LTD (NASDAQ), IP (SET), MOLECULIN BIOTECH INC (NASDAQ), JCT (SET), AGEX THERAPEUTICS INC (NYSE American), EXTRAWELL PHAR (HKEx), CITIUS PHARMACEUTICALS INC (NASDAQ), NOVAN INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AKORN INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), INVION LTD (ASX), PROPHASE LABS INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), DARE BIOSCIENCE INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), RACE ONCOLOGY LTD (ASX), NOXOPHARM LTD (ASX), BIOHLDG (Bursa), MANNATECH INC (NASDAQ), SINOLIFE UTD (HKEx), EDESA BIOTECH INC (NASDAQ), CELLMID LIMITED (ASX), ACER THERAPEUTICS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TALI DIGITAL LIMITED (ASX), PASHUN INT'L (HKEx), ADIAL PHARMACEUTICALS INC (NASDAQ), ACRUX (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), EXOPHARM LTD (ASX), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), Merck Sharp Dohme Pharma Tbk. (IDX), CRESO PHARMA LTD (ASX), SUNZEN (Bursa), FARMAFORCE LTD (ASX), NOVUS THERAPEUTICS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.005
+2.78 %
10 Days --0.006
-3.14 %
20 Days --0.040
-17.78 %
Medium Term Return 3 Months --0.035
-15.91 %
6 Months --0.015
-7.50 %
1 Year 0.006-0.015
-4.50 %
Annualised Return Annualised --
-4.50 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.180 - 0.295 Change From 1 Year Low +0.005 % Change From 1 Year Low (%) +2.78
Change From 1 Year High -0.110 % Change From 1 Year High (%) -37.29
2 Years Range 0.160 - 0.305 Change From 2 Years Low +0.025 % Change From 2 Years Low (%) +15.62
Change From 2 Years High -0.120 % Change From 2 Years High (%) -39.34
5 Years Range 0.160 - 0.305 Change From 5 Years Low +0.025 % Change From 5 Years Low (%) +15.62
Change From 5 Years High -0.120 % Change From 5 Years High (%) -39.34
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -28.85 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
03 Apr 2020 0.195 0.195 0.185 0.185 5,000 0.1920
02 Apr 2020 0.182 0.190 0.180 0.190 133,500 0.1860
01 Apr 2020 0.188 0.188 0.186 0.186 101,000 0.1870
31 Mar 2020 0.189 0.190 0.188 0.190 115,000 0.1891
30 Mar 2020 0.189 0.189 0.182 0.189 36,800 0.1889
27 Mar 2020 0.180 0.180 0.180 0.180 - -
26 Mar 2020 0.180 0.180 0.180 0.180 10,000 0.1800
25 Mar 2020 0.200 0.200 0.180 0.180 108,300 0.1844
24 Mar 2020 0.191 0.191 0.191 0.191 - -
23 Mar 2020 0.191 0.191 0.191 0.191 - -
20 Mar 2020 0.191 0.191 0.191 0.191 5,000 0.1910
19 Mar 2020 0.187 0.187 0.181 0.181 100,000 0.1851
18 Mar 2020 0.193 0.193 0.189 0.190 41,000 0.1906
17 Mar 2020 0.187 0.188 0.186 0.187 71,800 0.1866
16 Mar 2020 0.197 0.197 0.190 0.190 229,100 0.1936
13 Mar 2020 0.200 0.200 0.196 0.197 493,400 0.1994
12 Mar 2020 0.205 0.205 0.200 0.200 200,000 0.2048
11 Mar 2020 0.205 0.210 0.205 0.210 311,000 0.2070
10 Mar 2020 0.205 0.210 0.200 0.210 211,800 0.2070
09 Mar 2020 0.215 0.220 0.205 0.210 159,200 0.2100
06 Mar 2020 0.220 0.225 0.210 0.225 389,900 0.2171
05 Mar 2020 0.225 0.225 0.225 0.225 30,000 0.2250
Summary
Current 2 Weeks
(23 Mar 2020 to 03 Apr 2020)
0.191 0.200 0.180 0.185 509,600 -
Previous 2 Weeks
(09 Mar 2020 to 20 Mar 2020)
0.215 0.220 0.180 0.191 1,822,300 -
4 Weeks from
(10 Feb 2020 to 06 Mar 2020)
0.225 0.235 0.180 0.225 5,406,800 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.